BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 33338512)

  • 1. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
    J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of telomeres and telomerase in cirrhosis and liver cancer.
    Nault JC; Ningarhari M; Rebouissou S; Zucman-Rossi J
    Nat Rev Gastroenterol Hepatol; 2019 Sep; 16(9):544-558. PubMed ID: 31253940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing "stemness"-related markers.
    Kim H; Yoo JE; Cho JY; Oh BK; Yoon YS; Han HS; Lee HS; Jang JJ; Jeong SH; Kim JW; Park YN
    J Hepatol; 2013 Oct; 59(4):746-52. PubMed ID: 23685049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis.
    Miura N; Horikawa I; Nishimoto A; Ohmura H; Ito H; Hirohashi S; Shay JW; Oshimura M
    Cancer Genet Cytogenet; 1997 Jan; 93(1):56-62. PubMed ID: 9062581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
    Donaires FS; Scatena NF; Alves-Paiva RM; Podlevsky JD; Logeswaran D; Santana BA; Teixeira AC; Chen JJ; Calado RT; Martinelli ALC
    PLoS One; 2017; 12(8):e0183287. PubMed ID: 28813500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.
    Ma LJ; Wang XY; Duan M; Liu LZ; Shi JY; Dong LQ; Yang LX; Wang ZC; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Gao Q
    J Pathol; 2017 Dec; 243(4):407-417. PubMed ID: 28833123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data.
    Tornesello ML; Tornesello AL; Starita N; Cerasuolo A; Izzo F; Buonaguro L; Buonaguro FM
    Expert Opin Ther Targets; 2022 Sep; 26(9):767-780. PubMed ID: 36369706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
    Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
    Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
    Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
    Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
    J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive association of long telomeres with the invasive capacity of hepatocellular carcinoma cells.
    Ko E; Jung G
    Biochem Biophys Res Commun; 2014 May; 447(2):358-63. PubMed ID: 24732358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis.
    Oh BK; Kim H; Park YN; Yoo JE; Choi J; Kim KS; Lee JJ; Park C
    Lab Invest; 2008 Feb; 88(2):144-52. PubMed ID: 18158557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomere length and reactive oxygen species levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma.
    Ko E; Seo HW; Jung G
    Hepatology; 2018 Apr; 67(4):1378-1391. PubMed ID: 29059467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease.
    Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL
    Gastroenterology; 2007 Apr; 132(4):1465-75. PubMed ID: 17433324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma.
    Huang W; Zhou W; Li C; Yang Y; Shang YK; Chen C; Zhang J; Yao R; Wang P; Wen W; Liu HQ; Wang L; Li X; Bian H; Chen ZN
    Oncotarget; 2017 Apr; 8(16):26288-26297. PubMed ID: 28460432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cause-specific telomere factors deregulation in hepatocellular carcinoma.
    El Idrissi M; Hervieu V; Merle P; Mortreux F; Wattel E
    J Exp Clin Cancer Res; 2013 Sep; 32(1):64. PubMed ID: 24020493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma.
    Yu J; Yuan X; Sjöholm L; Liu T; Kong F; Ekström TJ; Björkholm M; Xu D
    Cancer Lett; 2018 Oct; 434():33-41. PubMed ID: 30017965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
    Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
    Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noncoding telomeric repeat-containing RNA inhibits the progression of hepatocellular carcinoma by regulating telomerase-mediated telomere length.
    Cao H; Zhai Y; Ji X; Wang Y; Zhao J; Xing J; An J; Ren T
    Cancer Sci; 2020 Aug; 111(8):2789-2802. PubMed ID: 32357278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations and telomeres during tumorigenesis.
    Lorbeer FK; Hockemeyer D
    Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.